Pacira BioSciences announced it will divest its iovera° business to Zimmer Biomet for up to $140 million, including $70 million upfront and $70 million in future milestones. The iovera° system is a drug-free, FDA-cleared device that uses cold therapy to relieve pain. This deal supports Pacira's strategy to focus on innovative biopharmaceuticals and will help strengthen its balance sheet. The transaction is expected to close in Q3 2026, with both companies collaborating on advancing a spasticity program.
Zimmer Biomet has appointed Chintan Desai as president of its Asia Pacific region, effective immediately. Desai brings nearly 30 years of leadership experience in the medical technology sector, including senior roles at Alcon and GE Healthcare. He re...
Zimmer Biomet Holdings announced its second quarter 2026 earnings conference call will be held on August 5 at 8:30 a.m. ET, with a news release detailing results available earlier that day. The call will be webcast live and available for replay on th...
